LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:OPMO), which was formerly known as Optical Molecular Imaging, Inc. (“ICT”), announced today that it has entered into an exclusive, worldwide license agreement with Cedars-Sinai Medical Center covering Cedars-Sinai’s technology for cellular therapies, including dendritic cell-based vaccines for brain tumors and other cancers, as well as other neurodegenerative disorders. The technology is covered by patent applications that have been filed in the United States.
